Mucosal Biomarker of Innate Immune Activation Predicts Response to Vedolizumab in Crohn's Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Inflammatory Bowel Diseases
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Mucosal Biomarker of Innate Immune Activation Predicts Response to Vedolizumab in Crohn's Disease
Inflamm. Bowel Dis. 2020 Sep 18;26(10)1554-1561, MT Osterman, IO Gordon, EM Davis, M Ciorba, SC Glover, B Abraham, F Khan, X Guo, EU Yee, FD Allard, B Claggett, B Shen, JJ LiuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.